Ethylsufonated Hyaluronic Acid Biopolymers

Tech ID: 23252 / UC Case 2013-127-0

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 10,000,582 06/19/2018 2013-127
European Patent Office Published Application 2981556 02/10/2016 2013-127

Brief Description

Hyaluronic acid (HyA) is a natural glycosaminoglycan (GAG) biopolymer with a variety of favorable biological properties, such as promoting cell growth, inhibiting thrombosis and modulating the tissue distribution of secreted growth factors. It is currently used in a variety of products to improve surface biocompatibility, as a substrate for tissue engineering and to control drug pharmacodynamics. A significant limiting factor for the use of HyA in medical applications is its degradation in vivo due to the high endogenous concentration of hyaluronidase and other glycolytic proteins. Depending on the tissue, the half-life of HyA can be as short as minutes, and when in contact with the blood, its half-life is approximately 1.5 hours. Therefore, current uses of HyA are limited to applications where its biomaterial properties are only required for a short duration of time.


UC Berkeley researchers have developed methods to improve the stability and half-life to HyA as well as implantable materials and drug delivery compositions containing the improved HyA.  The compositions can be used in a variety of medical applications, tissue engineering, drug delivery and methods of treatment.


Suggested uses

  • Tissue engineering (e.g., artificial tissue)
  • Drug delivery (e.g., drug delivery matrix)
  • Methods of treatment (e.g., diseased, damaged or lost tissue)


  • Improved stability
  • Biocompatible formulation

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As